Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334643 · ClinicalTrials.gov registry record · NA
Fiber Mix and Glycemic Response
A NA study of Type 2 Diabetes Mellitus, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03334643: Completed NA study of Type 2 Diabetes Mellitus, sponsored by Rutgers, The State University of New Jersey.
NCT03334643 is a NA study of Type 2 Diabetes Mellitus that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 19 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03334643, a NA study of Type 2 Diabetes Mellitus, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This study determines the acute effect of a dietary fiber mix on blood glucose levels. Participants will consume the fiber mix as a drink and we will monitor changes in blood glucose levels. All participants will consume white bread as the control food.
Primary Outcome
Circulating blood glucose concentration will be measured using a continuous glucose monitoring system (FreeStyle Libre Pro, Abbott Diabetes Care)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Fiber mix
Study Locations (1)
New Jersey
- Institute for Food, Nutrition & Health - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2019-02-01 |
| Phase | NA |
What the finished NCT03334643 record still lists
NCT03334643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Fiber mix is the first listed.
NCT03334643 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03334643 about?
NCT03334643 is a clinical study titled "Fiber Mix and Glycemic Response". This study determines the acute effect of a dietary fiber mix on blood glucose levels. Participants will consume the fiber mix as a drink and we will monitor changes in blood glucose levels. All participants will consume white bread as the control food.
What is the current status of trial NCT03334643?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2018-06-04. Estimated completion is 2019-02-01.
What conditions does trial NCT03334643 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT03334643?
The interventions under investigation include: Fiber mix (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03334643?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03334643 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03334643's enrollment target sits among peer trials
19 115th of 130 higher than 15 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
The GRoceries Aimed at Increasing Nutrition Study
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
RECRUITING · NA
-
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
ACTIVE NOT RECRUITING · NA
-
Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI